McKesson to Pay $190 Million to Resolve False-Claims Allegations

In a news release, the U.S. Justice Department said that states can separately negotiate resolutions with McKesson pertaining to claims based on the states' shares of Medicaid overpayments.

Story in progress.

Read this story:


McKesson Corp., a San Francisco-based drug wholesaler and health information technology provider, will pay the U.S. more than $190 million to resolve claims it reported inflated prices for several prescription drugs, causing Medicaid to overpay for the drugs.